Autres langues Indivior Pharmaceuticals, Inc. Xetra

Actions

E7P

US45579U1097

Produits pharmaceutiques

Temps réel estimé Tradegate 17:13:19 31/08/2026			Varia. 5j.	Varia. 1 janv.
29,90 ^EUR	-0,99%		-6,79%	-

03/08	Indivior Pharmaceuticals, Inc. propose un dividende exceptionnel en numéraire	CI
03/08	Indivior Pharmaceuticals, Inc. et Supernus Pharmaceuticals, Inc. nomment Timothy C. Dec au poste de directeur financier de Supernus, Inc.	CI

Autres langues

03/08	Indivior Pharmaceuticals, Inc. Enters into Senior Secured Term Loan Facility
03/08	Indivior Pharmaceuticals, Inc. Proposes Special Cash Dividend
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Timothy C. Dec as Chief Financial Officer of Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. Raises Earnings Guidance for the Fiscal Year 2026
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Member of the Board of the Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. entered into a definitive agreement to acquire Supernus Pharmaceuticals, Inc. for $3.6 billion in a merger of equals transaction.
03/08	Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Tranche Update on Indivior Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 26, 2026.
03/08	Supernus, Indivior merge to strengthen neuroscience drug portfolio
03/08	Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal
03/08	Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger
03/08	Indivior Pharmaceuticals Q2 Non-GAAP Earnings, Revenue Rise; 2026 Sales Outlook Upgraded
03/08	(INDV) Indivior Expects 2026 Net Revenue Range $1.30B - $1.37B, vs. FactSet Est of $1.26B
03/08	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q2 Revenue $343.0M, vs. FactSet Est of $307.6M
03/08	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $1.15 per Share, vs. FactSet Est of $0.89
30/07	Indivior Pharmaceuticals : Half a Million Reasons to Hope
29/06	Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Value-Defensive Index
29/06	Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Growth-Defensive Index
29/06	Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Defensive Index
10/06	Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing
21/05	Indivior Pharmaceuticals - New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
20/05	Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine
04/05	Indivior Pharmaceuticals Enters $175 Million Accelerated Share Repurchase Agreement
30/04	Tranche Update on Indivior Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 26, 2026.